Press release from the American Society for Bone and Mineral Metabolism 2022 Annual Meeting and Vitamin D Workshop 2022
https://doi.org/10.14341/osteo12966
Abstract
ASBMR 2022 Annual Meeting and Vitamin D Workshop 2022 — the key international events in the field of metabolic diseases of the skeleton and pathology of mineral metabolism — were held in September 2022. During the conferences the results of the latest research were presented, promising areas of further research were discussed, as well as debates and author’s sessions on controversial issues were held. The article provides a brief overview of the events.
About the Authors
A. Yu. Zhukov
Endocrinology Research Centre
Russian Federation
Russian Federation
Artem Yu. Zhukov, MD
11 Dmitriya Ulyanova street, 117036 Moscow
Scopus Author ID: 57214675478;
eLibrary SPIN: 8513-7785
A. A. Povaliaeva
Endocrinology Research Centre
Alexandra A. Povaliaeva, MD, PhD
Moscow
Researcher ID: U-7144-2018;
Scopus Author ID: 57219666529;
eLibrary SPIN: 1970-2811
References
1. Chor-Wing Sing, Tzu-Chieh Lin, Sharon Bartholomew, et al. Global Epidemiology of Hip Fracture — Secular Trends of Incidence, Treatment Rate, and Mortality from 2005 to 2018; A Multinational Realworld Study with Common Data Model [1017]
2. Weiwen Chen, Thach Tran, Dana Bliuc, et al. Are ankle fractures benign: The 45 and Up study, a population-based cohort study of New South Wales, Australia? [SUN-493]
3. Andrea Burden, Theresa Burkard, Martina Rauner, et al. Increased fracture risk associated with iron overload: a population-based matched cohort study [LB MON-1115]
4. Fjorda Koromani, Elizabeth Benz, Ling Oei, et al. Fracture risk is increased in individuals with COPD independent of smoking status and other risk factors [SUN-568]
5. Kristian Axelsson, Henrik Litsne, Konstantina Kousoula, et al. The Clinical Relevance of Type 2 Diabetes for Fracture Risk – a Nationwide Cohort Study of Swedish Men and Women [1090]
6. Ceri Richards, Richard Stevens, Lisa Lix, et al. Fracture Risk Prediction in Rheumatoid Arthritis From the Modern Era: Validation of FRAX© with Bone Mineral Density for Incident Major Osteoporotic Fractures [1019]
7. William Leslie, Suzanne Morin, Lisa Lix, et al. Adjusting FRAX Estimates of Fracture Probability Based Upon a Positive Vertebral Fracture Assessment: The Manitoba BMD Registry [1020]
8. Tina Kelley, Elinor Mody, Robert Yood, et al. Crystal Bone: Validation of a Novel AI/ML Algorithm in the Optum Reliant dataset to Identify Patients at Risk of Osteoporotic Fracture in the Next 2 Years [FRI-471]
9. Mahdi Imani, Thang Ngoc Quoc Dao, Peggy Cawthon, et al. Development of a fully automatic segmentation and quantification method for evaluating musculoskeletal tissues in the proximal hip: The Osteoporotic Fractures in Men (MrOS) Study [LB SAT-861]
10. Rajesh Jain, Tamara Vokes. Visceral Fat has Stronger Negative Effects on Bone Density than Subcutaneous Fat: A Cross-Sectional Study of NHANES 2011-2018 [FRI-550]
11. Sungjae Shin, Namki Hong, Sookyoung Han, et al. Romosozumab is associated with greater gain in bone mineral density at lumbar spine compared to denosumab in glucocorticoid-induced osteoporosis [SUN-592]
12. Felicia Cosman, Mary Oates, Donald Betah, et al. One Year of Romosozumab Followed by One Year of Denosumab Compared With Two Years of Denosumab: BMD and Fracture Results From the FRAME and FRAME Extension Studies [1055]
13. Michael McClung, Donald Betah, Cynthia Deignan, et al. Romosozumab Efficacy in Postmenopausal Women Without Prior Fracture Who Fulfill AACE Criteria for Osteoanabolic Therapy: Post-Hoc Analysis of Clinical Trial Data [1076]
14. Jie Zheng, George Davey Smith, Maryam Kavousi, et al. Lowering of circulating sclerostin may increase risk of atherosclerosis and its risk factors: evidence from a genome-wide association meta-analysis followed by Mendelian randomization [1021]
15. Leslie Spangler, Carrie Nielson, M Alan Brookhart, et al. Myocardial Infarction and Stroke Risks Among Patients Who Initiated Treatment with Denosumab or Zoledronic Acid for Osteoporosis [1022]
16. Judith Everts-Graber, Stephan Reichenbach, Brigitta Gahl, et al. Long-term Denosumab Therapy and Subsequent Zoledronate Treatment: Observations in a Real-World Setting [1018]
17. Joy Tsai, Grace Sassana, Sabashini Ramchand, et al. Comparison of Alendronate versus Raloxifene after Denosumab Discontinuation (CARD): A Randomized Controlled Trial [1078]
18. Vrisha Madhuri, Sowmya Ramesh, Åsa Ekblad Nordberg, et al. An evaluation of safety and efficacy of multiple intravenous and intraosseous injections of fetal liver-derived MSCs in children with Osteogenesis Imperfecta (BOOST to BRITTLE BONES) - An exploratory open-label phase I/ II clinical trial [LB SAT-899]
19. Luis Fernandez de Castro, Zachary Michel, Jocelyn Taylor, et al. RANKL Inhibition Decreases Fibrous Cell Proliferation and Increases Lesional Bone Formation in Fibrous Dysplasia [1056]
20. Leanne Ward, Erik Imel, Hamilton Cassinelli, et al. Characterizing the Impact of Burosumab on Bone Health in Children with X-Linked Hypophosphatemia: Results from Year 1 of the Disease Monitoring Program [1079]
21. Iris R. Hartley, Rachel I. Gafni, Kelly L. Roszko, et al. Encaleret (CLTX-305) Normalizes Mineral Homeostasis Parameters in Patients with Autosomal Dominant Hypocalcemia Type 1 in a 6-month Phase 2 Study (NCT04581629) [1066]
22. Mishaela Rubin, Bart Clarke, Lorenz C. Hofbauer, et al. TransCon PTH for Hypoparathyroidism: Skeletal Dynamics Through Week 58 of the Phase 2 PaTH Forward Trial [1080]
Review
For citations:
Zhukov A.Yu., Povaliaeva A.A. Press release from the American Society for Bone and Mineral Metabolism 2022 Annual Meeting and Vitamin D Workshop 2022. Osteoporosis and Bone Diseases. 2022;25(4):56-58. (In Russ.) https://doi.org/10.14341/osteo12966
Views:
591
This work is licensed under a Creative Commons Attribution-NonCommercial-NoDerivatives 4.0 International License (CC BY-NC-ND 4.0).
Email this article 
